Drug Profile

Tasronetide - Find Therapeutics

Alternative Names: FTX-101

Latest Information Update: 19 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Find Therapeutics
Class Anti-inflammatories; Eye disorder therapies; Peptides
Mechanism of Action Neuropilin-1 modulators; PLXNA1 protein modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I Multiple sclerosis; Optic neuritis

Most Recent Events

19 Jan 2026 Find Therapeutics plans to initiate a phase II trial
09 Jan 2026 Phase-I clinical trials in Multiple sclerosis (unspecified route), prior to January 2026
17 Apr 2025 Find Therapeutics terminates phase I trial in Optic neuritis (In volunteers) in USA due to study objectives met (IV & SC) (NCT06617546)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com